Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Calidi Biotherapeutics, Inc. (CLDI) had Stock-Based Compensation of $1.66M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-10.82M |
|
-- |
|
-- |
|
$5.05M |
|
$-5.05M |
|
$-0.12M |
|
$-5.17M |
|
$-5.17M |
|
$-5.18M |
|
$-5.18M |
|
$-5.18M |
|
$-5.18M |
|
$-5.05M |
|
$-4.62M |
|
4.91M |
|
4.91M |
|
$-2.21 |
|
$-2.21 |
|
| Balance Sheet Financials | |
$11.03M |
|
$0.85M |
|
$3.00M |
|
$14.03M |
|
$5.19M |
|
$0.80M |
|
$1.64M |
|
$6.83M |
|
$7.20M |
|
$7.20M |
|
$7.20M |
|
6.91M |
|
| Cash Flow Statement Financials | |
$-16.25M |
|
$-0.09M |
|
$17.12M |
|
$9.81M |
|
$10.59M |
|
$0.79M |
|
|
Stock-Based Compensation |
$1.66M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.12 |
|
-- |
|
-- |
|
0.10 |
|
0.18 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-71.98% |
|
-71.98% |
|
-36.93% |
|
-64.80% |
|
$1.04 |
|
$-3.33 |
|
$-3.31 |
|